FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800772239> ?p ?o ?g. }

• W2800772239 endingPage "1912" @default.
• W2800772239 startingPage "1905" @default.
• W2800772239 abstract "Purpose Although programmed death (PD)-1 pathway inhibitors are now used in nearly all patients with advanced non–small-cell lung cancer (NSCLC), the large number of patients with NSCLC and concurrent autoimmune disease (AID) have been universally excluded from immunotherapy clinical trials. Therefore, the safety of PD-1 and PD-ligand 1 (PD-L1) inhibitors in patients with NSCLC and underlying AID is currently unknown. Methods As part of a multi-institutional effort, we retrospectively collected clinicopathologic data from patients with NSCLC and a history of AID who received monotherapy with either a PD-1 or a PD-L1 (herein referred to as PD-[L]1) inhibitor. Qualifying AIDs included but were not limited to: rheumatologic, neurologic, endocrine, GI, and dermatologic conditions. Results We identified 56 patients with NSCLC and an AID who received a PD-(L)1 inhibitor. At the time of treatment initiation, 18% of patients had active AID symptoms and 20% were receiving immunomodulatory agents for their AID. A total of 55% of patients developed an AID flare and/or an immune-related adverse event (irAE). Exacerbation of the AID occurred in 13 patients (23% of the whole cohort), four of whom required systemic corticosteroids. Immune-related adverse events occurred in 21 patients (38%). Among irAEs, 74% were grade 1 or 2 and 26% were grade 3 or 4; eight patients required corticosteroids for irAE management. PD-(L)1 therapy was permanently discontinued in eight patients (14%) because of irAEs. The overall response rate to immunotherapy in this population was 22%. Conclusion In patients with NSCLC with AID treated with a PD-(L)1 inhibitor, exacerbation of AID occurred in a minority of patients. The incidence of irAEs was similar to reported rates in clinical trials where patients with AID were excluded. Adverse events were generally manageable and infrequently led to permanent discontinuation of immunotherapy." @default.
• W2800772239 created "2018-05-17" @default.
• W2800772239 creator A5005948108 @default.
• W2800772239 creator A5010761253 @default.
• W2800772239 creator A5012878891 @default.
• W2800772239 creator A5018334489 @default.
• W2800772239 creator A5018666301 @default.
• W2800772239 creator A5029805571 @default.
• W2800772239 creator A5039160380 @default.
• W2800772239 creator A5080739298 @default.
• W2800772239 creator A5081227348 @default.
• W2800772239 creator A5082506495 @default.
• W2800772239 creator A5086249998 @default.
• W2800772239 date "2018-07-01" @default.
• W2800772239 modified "2023-10-16" @default.
• W2800772239 title "Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders" @default.
• W2800772239 cites W2104347254 @default.
• W2800772239 cites W2143488876 @default.
• W2800772239 cites W2156353875 @default.
• W2800772239 cites W2168599228 @default.
• W2800772239 cites W2193769500 @default.
• W2800772239 cites W2198093519 @default.
• W2800772239 cites W2416974268 @default.
• W2800772239 cites W2508205285 @default.
• W2800772239 cites W2525217971 @default.
• W2800772239 cites W2527905628 @default.
• W2800772239 cites W2529904548 @default.
• W2800772239 cites W2559488318 @default.
• W2800772239 cites W2560367415 @default.
• W2800772239 cites W2567564314 @default.
• W2800772239 cites W2572174216 @default.
• W2800772239 cites W2753065806 @default.
• W2800772239 cites W2781601010 @default.
• W2800772239 doi "https://doi.org/10.1200/jco.2017.77.0305" @default.
• W2800772239 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6553840" @default.
• W2800772239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29746230" @default.
• W2800772239 hasPublicationYear "2018" @default.
• W2800772239 type Work @default.
• W2800772239 sameAs 2800772239 @default.
• W2800772239 citedByCount "245" @default.
• W2800772239 countsByYear W28007722392018 @default.
• W2800772239 countsByYear W28007722392019 @default.
• W2800772239 countsByYear W28007722392020 @default.
• W2800772239 countsByYear W28007722392021 @default.
• W2800772239 countsByYear W28007722392022 @default.
• W2800772239 countsByYear W28007722392023 @default.
• W2800772239 crossrefType "journal-article" @default.
• W2800772239 hasAuthorship W2800772239A5005948108 @default.
• W2800772239 hasAuthorship W2800772239A5010761253 @default.
• W2800772239 hasAuthorship W2800772239A5012878891 @default.
• W2800772239 hasAuthorship W2800772239A5018334489 @default.
• W2800772239 hasAuthorship W2800772239A5018666301 @default.
• W2800772239 hasAuthorship W2800772239A5029805571 @default.
• W2800772239 hasAuthorship W2800772239A5039160380 @default.
• W2800772239 hasAuthorship W2800772239A5080739298 @default.
• W2800772239 hasAuthorship W2800772239A5081227348 @default.
• W2800772239 hasAuthorship W2800772239A5082506495 @default.
• W2800772239 hasAuthorship W2800772239A5086249998 @default.
• W2800772239 hasBestOaLocation W28007722392 @default.
• W2800772239 hasConcept C121608353 @default.
• W2800772239 hasConcept C126322002 @default.
• W2800772239 hasConcept C143998085 @default.
• W2800772239 hasConcept C197934379 @default.
• W2800772239 hasConcept C2776256026 @default.
• W2800772239 hasConcept C2777014857 @default.
• W2800772239 hasConcept C2777701055 @default.
• W2800772239 hasConcept C2908647359 @default.
• W2800772239 hasConcept C71924100 @default.
• W2800772239 hasConcept C99454951 @default.
• W2800772239 hasConceptScore W2800772239C121608353 @default.
• W2800772239 hasConceptScore W2800772239C126322002 @default.
• W2800772239 hasConceptScore W2800772239C143998085 @default.
• W2800772239 hasConceptScore W2800772239C197934379 @default.
• W2800772239 hasConceptScore W2800772239C2776256026 @default.
• W2800772239 hasConceptScore W2800772239C2777014857 @default.
• W2800772239 hasConceptScore W2800772239C2777701055 @default.
• W2800772239 hasConceptScore W2800772239C2908647359 @default.
• W2800772239 hasConceptScore W2800772239C71924100 @default.
• W2800772239 hasConceptScore W2800772239C99454951 @default.
• W2800772239 hasIssue "19" @default.
• W2800772239 hasLocation W28007722391 @default.
• W2800772239 hasLocation W28007722392 @default.
• W2800772239 hasLocation W28007722393 @default.
• W2800772239 hasLocation W28007722394 @default.
• W2800772239 hasOpenAccess W2800772239 @default.
• W2800772239 hasPrimaryLocation W28007722391 @default.
• W2800772239 hasRelatedWork W1992577796 @default.
• W2800772239 hasRelatedWork W2110265450 @default.
• W2800772239 hasRelatedWork W2130829219 @default.
• W2800772239 hasRelatedWork W2156169457 @default.
• W2800772239 hasRelatedWork W2553873465 @default.
• W2800772239 hasRelatedWork W2801381949 @default.
• W2800772239 hasRelatedWork W2952884403 @default.
• W2800772239 hasRelatedWork W4309103225 @default.
• W2800772239 hasRelatedWork W4311699418 @default.
• W2800772239 hasRelatedWork W2130939671 @default.
• W2800772239 hasVolume "36" @default.
• W2800772239 isParatext "false" @default.

• next